Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Lieberman, Frank S.; Yazbeck, Victor; Raptis, Anastasios; Felgar, Raymond E.; Boyiadzis, Michael

doi:10.1007/s11060-011-0739-6

Cited by 26 publications

(33 citation statements)

References 36 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…38 In solid organ transplant recipients the median time to CNS-PTLD is 4.4 years, 38 while in CNS-PTLD patients who received allo-HSCT disease developed after 2e24 months. 40,41 In both types of transplant, M:F ratio is about 2. 38 The primary CNS-PTLD needs to be considered separately as it has significantly inferior survival compared to non-CNS PTLD and its therapy is different than in other forms of PTLD.…”

Section: Monomorphic Ptldmentioning

confidence: 98%

Post-transplant lymphoproliferative disorders

Torlakovic

Bailey

2012

Diagnostic Histopathology

View full text Add to dashboard Cite

Section: Monomorphic Ptldmentioning

confidence: 98%

Post-transplant lymphoproliferative disorders

Torlakovic

Bailey

2012

Diagnostic Histopathology

View full text Add to dashboard Cite

“…4 This disorder encompasses a heterogeneous group of disorders that can range from an indolent polyclonal proliferation to aggressive lymphomas. 5 Posttransplant lymphoproliferative disorder is thought to be the result of immunosuppressive-induced impairment of T-cell immunity, leading to an uncontrolled proliferation of EBVtransformed B lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

“…4,10,13 Prospective and retrospective studies using rituximab with temozolomide in primary CNS lymphoma have shown it to be an effective and well-tolerated treatment modality. 3,14 Evens and associates showed by univariate analysis that treatment with rituximab was associated with a significant improvement in PFS.…”

Section: Discussionmentioning

confidence: 99%

“…The pacemaker lead was explanted; 2 weeks into her course of antibiotics, imaging displayed marked radiologic improvement. During her long course of antibiotics, Mashya Abbassi, 1 Roger Riley, 2 Mark Malkin, 3,4 Yang Tang, 5 Bipin Rajendran, 5 Victor Yazbeck 1,4 From the the 1 School of Internal Medicine, the 2 Department of Pathology, the 3 Department of which included nafcillin, cephalexin, micafungin, and fluconazole, she developed no new neurologic findings, and brain imaging continued to show radiologic improvement with no new lesions.…”

Section: Case Reportmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report

Abbassi

Riley²,

Malkin³

et al. 2019

Exp Clin Transplant

Self Cite

View full text Add to dashboard Cite

Posttransplant lymphoproliferative disorder is a serious complication of solid-organ transplant. Extranodal involvement is common; however, isolated involvement of the central nervous system is extremely rare and represents a particularly difficult therapeutic challenge with no current consensus on optimal treatment. Here, we describe a 70-year-old woman who developed Epstein-Barr virus-related primary central nervous system lymphoma 19 months after kidney transplant. Immunosuppression was reduced, and the patient was started on high-dose methotrexate, which was complicated by acute kidney injury and discontinued. She then received a rituximab and temozolomide chemotherapeutic regimen and achieved complete clinical response. Seventeen months after diagnosis, she is alive and has not developed any other posttransplant lymphoproliferative disorder. We review the current literature and discuss treatment options for patients with primary central nervous system posttransplant lymphoproliferative disorder following kidney transplant.

show abstract

“…Till date, only 14 cases have been reported in the literature, and none occurred in lymphoma patients. [2,3] In this paper, we report the first case of a B-cell lymphoma presenting with an isolated PTLD in the CNS after HSCT.…”

Section: Introductionmentioning

confidence: 97%

Isolated cerebral post-transplant lymphoproliferative disorder in a lymphoma recipient

2013

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorder (PTLD) can occur after solid organ transplantation (SOT) or hematopoietic stem cell transplantation (HSCT). The majority of PTLDs are related to the reactivation of Epstein-Barr virus (EBV) in the lymphoid organs. PLTDs in HSCT recipients tend to present with systemic involvement, and isolated PTLD in these patients is rare. Only 14 isolated cerebral PTLDs have been reported in HSCT recipients, and none have been reported in lymphoma patients. When diagnosing PTLD in a lymphoma patient, it is challenging to discriminate between a PTLD that originated from previous disease and a newly developed clone and to distinguish between donor and recipient origin. In this report, we present the first case of a B-cell lymphoma patient who developed isolated PTLD in the CNS, and we confirmed that the PTLD originated in a distinct clone and from a different origin. Furthermore, the role of EBV-DNA monitoring in such patients is discussed.

show abstract

Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation

Cited by 26 publications

References 36 publications

Post-transplant lymphoproliferative disorders

Post-transplant lymphoproliferative disorders

Treatment of Primary Central Nervous System Posttransplant Lymphoproliferative Disorder in an Adult Kidney Transplant Recipient: A Case Report

Isolated cerebral post-transplant lymphoproliferative disorder in a lymphoma recipient

Contact Info

Product

Resources

About